Browse by author
Lookup NU author(s): Professor Marco Carrozzo
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Pemphigus vulgaris (PV) is the most common type of pemphigus. PV pathogenesis is still debated, and treatment remains challenging. We investigated five controversial topics: (1) What are the target antigens in PV? (2) Do desmogleins adequately address PV pathophysiology? (3) How does acantholysis occur in PV? (4) Is PV still a lethal disease? (5) What is the role of rituximab (RTX) in PV treatment? Results from extensive literature searches suggested the following: (1) Target antigens of PV include a variety of molecules and receptors that are not physically compartmentalized within the epidermis. (2) PV is caused by a variety of autoantibodies to keratinocyte self-antigens, which concur to cause blistering by acting synergistically. (3) The concept of apoptolysis distinguishes the unique mechanism of autoantibody-induced keratinocyte damage in PV from other known forms of cell death. (4) PV remains potentially life-threatening largely because of treatment side effects, but it is uncertain which therapies carry the highest likelihood of lethal risk. (5) RTX is a very promising treatment option in patients with widespread recalcitrant or life-threatening PV. RTX’s cost is an issue, its long-term side effects are still unknown, and randomized controlled trials are needed to establish the optimal dosing regimen.
Author(s): Cirillo N, Cozzani E, Carrozzo M, Grando SA
Publication type: Article
Publication status: Published
Journal: Oral Diseases
Print publication date: 15/02/2012
ISSN (print): 1354-523X
ISSN (electronic): 1601-0825
Publisher: Wiley-Blackwell Publishing, Inc.
Altmetrics provided by Altmetric